Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886426 | 0.93 | FTO (0.42) | L3MBTL1CTSBCTSSCTSKCAPN1 | |
| SCHEMBL22886561 | 0.91 | L3MBTL1 (0.42) | L3MBTL1CNR1CTSBCTSSCTSK | |
| SCHEMBL22886539 | 0.86 | ALDH1A1 (0.42) | CAPN1 | |
| SCHEMBL22886543 | 0.85 | L3MBTL1 (0.46) | L3MBTL1CAPN1SCN3AFTO | |
| SCHEMBL21410716 | 0.84 | FTO (0.42) | L3MBTL1ATMCAPN1FTO | |
| SCHEMBL20028431 | 0.84 | CAPN1 (0.53) | CTSBCTSSCAPN1 | |
| SCHEMBL21854063 | 0.84 | CAPN1 (0.53) | CTSBCTSSCAPN1 | |
| SCHEMBL22886773 | 0.82 | CAPN1 (0.51) | CAPN1 | |
| SCHEMBL21411218 | 0.82 | CAPN1 (0.40) | L3MBTL1CAPN1 | |
| SCHEMBL20027849 | 0.81 | CAPN1 (0.48) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | L3MBTL1 3275/4885CNR1 3398/4885CTSB 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.